New drug BL0175 tested for advanced Hormone-Positive cancers
NCT ID NCT06738966
First seen Jan 17, 2026 · Last updated May 14, 2026 · Updated 13 times
Summary
This early-phase study tests an investigational drug called BL0175 in postmenopausal women with advanced breast, ovarian, or endometrial cancer that is hormone receptor-positive. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink or control the cancer. Only 9 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jinan Central Hospital
RECRUITINGJinan, Shandong, 250000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.